An overview of SCLC
For US Healthcare Providers
Program Objectives
Describe the unmet need for some patients with SCLC with currently available treatment options
Explain the molecular subtypes of SCLC based on the expression of transcription factors
Differentiate the novel biomarkers emerging in SCLC
Discuss how the emergence of biomarkers may address some unmet patient needs in SCLC
Presented By
Christine M. Lovly, MD, PhD
Associate Professor of Medicine (Division of Hematology &
Oncology)
Ingram Associate Professor
of Cancer Research
Vanderbilt University Medical
Center and Vanderbilt-Ingram Cancer Center
Oncology)
Ingram Associate Professor
of Cancer Research
Vanderbilt University Medical
Center and Vanderbilt-Ingram Cancer Center
Carl M. Gay, MD, PhD
Assistant Professor, Department of
Thoracic/Head and Neck Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson
Cancer Center
Assistant Professor, Department of
Thoracic/Head and Neck Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson
Cancer Center
This program is sponsored by Daiichi-Sankyo and is intended for US healthcare professionals only
© 2025 Daiichi Sankyo, Inc. PP-US-7300-0038 03/25